Nebenwirkungen · Lantus
Lantus 100 units/ml solution for injection in a vial Lantus 100 units/ml solution for injection in a cartridge Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen · Abschnitt 4.8 · PDF-Seite 9
HOS-091025 · Präparat HOS-084169
Paediatric population In general, the safety profile for children and adolescents (≤18 years of age) is similar to the safety profile for adults. The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤18 years of age) than in adults. Clinical study safety data are not available for children under 2 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T11:08:00Z · SHA-256 675b799bf0c080ebd4fa5597f08423cd1cb573541330b2cc6a5cdd808c8fe620 · Passage f590da2030c916347185bca89ff940a6517497726678b03160fe0aac34dfec5e · Zeichen 4139–4634 im Abschnitt